Thai holy basil and MASLD: a rat study

A rat study published in Food Research International in October 2026 found that a flower extract from Ocimum sanctum L. (Thai holy basil) reduced multiple markers of lipid dysfunction and liver inflammation in animals fed a high-fat, high-fructose diet to induce metabolic dysfunction-associated steatotic liver disease (MASLD)^[1]. The findings add to a body of preclinical research on holy basil's hepatoprotective properties, but the study involved rats, not humans, and no clinical data exists for this specific preparation.

What MASLD is and why it matters

MASLD is the current clinical name for what was formerly called non-alcoholic fatty liver disease (NAFLD). It describes excess fat accumulation in the liver in people who drink little or no alcohol, typically in the setting of obesity, type 2 diabetes, or metabolic syndrome. The condition affects roughly 24% of US adults and up to 75% of people with overweight, according to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)^[2]. Liver inflammation in MASLD can progress to metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), cirrhosis, and liver failure.

Treatment options for MASLD remain thin. Lifestyle change and weight loss are the primary interventions. A handful of pharmaceutical candidates are in late-stage trials, and GLP-1 receptor agonists used for obesity and type 2 diabetes have shown signals of liver benefit in secondary analyses. Against that backdrop, preclinical research on plant-derived compounds is active, including the new Thai holy basil flower study.

What the rat study tested and found

Inchai, Phatsara, Yoonakorn, and colleagues at Chiang Mai University fed rats a high-fat, high-fructose diet for eight weeks to produce MASLD-like liver changes, then administered extracts prepared from Ocimum sanctum L. flowers^[1]. The research group measured lipid profiles (total cholesterol, triglycerides, LDL, HDL), liver enzymes (ALT, AST), and histological markers of liver inflammation and fat accumulation in tissue samples.

The extract-treated animals showed reductions in circulating triglycerides and total cholesterol alongside lower liver enzyme readings compared to untreated MASLD-diet rats. Histological analysis showed less fat deposition and reduced inflammation in liver tissue from treated animals. The study attributed the activity partly to phenolic compounds and eugenol present in the flower extract.

These are the kinds of findings that justify designing a next-stage study. They do not establish that the extract works in humans, at what dose, or whether a standardised preparation would replicate the result.

Why the translation gap matters here

Animal-to-human translation in liver disease research has a poor track record. Dozens of compounds that reduced liver fat or inflammation in rodent MASLD models have not gone on to show benefit in clinical trials. The biology of MASLD in humans is more complex and heterogeneous than in diet-induced rodent models, where the condition develops quickly and uniformly in a way that does not fully mirror the gradual, multifactorial human disease.

Ocimum sanctum is traditionally used across South and Southeast Asia, and earlier animal research has documented anti-inflammatory and lipid-modifying activity from leaf and seed preparations. Liver-specific data from the flower preparation, particularly in a MASLD model, is new territory. But "new in a rat model" is a very long way from "effective in humans."

There is also no standardised Ocimum sanctum flower supplement on the market; commercially available holy basil products vary widely in preparation, plant part, and phytochemical content. Even if the extract in this study works as described, a consumer product using dried leaf or seed would not be the same thing.

Where this sits in the MASLD treatment picture

For readers tracking the clinical frontier of MASLD, the more directly actionable evidence involves weight-loss-first strategies. Semaglutide (Ozempic, Wegovy) has been evaluated in MASH specifically in the ESSENCE trial, and the GLP-1 receptor agonist class broadly shows reductions in liver fat as a secondary benefit in obesity and type 2 diabetes trials. Those findings involve regulated medicines in controlled human trials, not plant extracts in rats.

The MASLD space also intersects with conditions such as type 2 diabetes and obesity that GLP-1 class agents directly target. If you have MASLD alongside one of those conditions, the question of pharmacological treatment belongs with a gastroenterologist or hepatologist who can assess your individual degree of fibrosis, metabolic status, and eligibility for emerging interventions. There is no supplement, herbal or otherwise, with demonstrated efficacy in human MASLD.

What this study does not show

The Ocimum sanctum flower study does not show that Thai holy basil treats, prevents, or reverses MASLD in humans. It does not establish a therapeutic dose. It does not show the extract is safe at any particular level in humans. It does not compare the extract to any approved intervention. The study is a mechanistic preclinical signal, which is the appropriate first step in a research programme, but it is only that step.

If further research confirms the lipid-lowering and anti-inflammatory signals in more refined animal models, a human pilot study might follow. That process typically takes years. As of September 2026, there are no registered clinical trials testing Ocimum sanctum flower extract for MASLD.